Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 276

1.

Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.

Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B.

Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):172-6.

PMID:
22484586
[PubMed - indexed for MEDLINE]
Free Article
2.

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.

Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.

J Viral Hepat. 2007 Nov;14(11):767-74.

PMID:
17927612
[PubMed - indexed for MEDLINE]
3.

[Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].

Cao XX, Li J, Qiu LM, Luo YW, Chen YH, Ran Y.

Zhonghua Gan Zang Bing Za Zhi. 2009 Sep;17(9):641-4. Chinese.

PMID:
19785947
[PubMed - indexed for MEDLINE]
4.

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW.

J Gastroenterol Hepatol. 2004 Nov;19(11):1276-82.

PMID:
15482535
[PubMed - indexed for MEDLINE]
5.

An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.

Yao G, Cui Z, Wang B, Yao J, Zeng M.

Chin Med J (Engl). 2002 Dec;115(12):1814-8.

PMID:
12622930
[PubMed - indexed for MEDLINE]
Free Article
6.

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H.

Intervirology. 2003;46(3):182-9.

PMID:
12867757
[PubMed - indexed for MEDLINE]
7.

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.

Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.

J Viral Hepat. 2005 Jul;12(4):398-404.

PMID:
15985011
[PubMed - indexed for MEDLINE]
8.

A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.

Hepatobiliary Pancreat Dis Int. 2004 May;3(2):188-93.

PMID:
15138107
[PubMed - indexed for MEDLINE]
Free Article
9.

The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.

Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.

Antivir Ther. 2006;11(4):447-55.

PMID:
16856618
[PubMed - indexed for MEDLINE]
10.

The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.

Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T.

J Gastroenterol. 2004;39(3):260-7.

PMID:
15065004
[PubMed - indexed for MEDLINE]
11.

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; Asia Hepatitis Lamivudine Study Group.

Hepatology. 2001 Jun;33(6):1527-32.

PMID:
11391543
[PubMed - indexed for MEDLINE]
12.

Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.

Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.

Liver Int. 2007 Dec;27(10):1349-55.

PMID:
18036099
[PubMed - indexed for MEDLINE]
13.

Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.

Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.

J Med Virol. 2005 Mar;75(3):391-8.

PMID:
15648063
[PubMed - indexed for MEDLINE]
14.

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.

Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, Wong BC, Lai CL.

Antivir Ther. 2006;11(6):779-86.

PMID:
17310822
[PubMed - indexed for MEDLINE]
15.

Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.

Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL.

Antivir Ther. 2009;14(5):679-85.

PMID:
19704171
[PubMed - indexed for MEDLINE]
16.

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.

Chang ML, Chien RN, Yeh CT, Liaw YF.

J Hepatol. 2005 Jul;43(1):72-7. Epub 2005 Apr 26.

PMID:
15896869
[PubMed - indexed for MEDLINE]
17.

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.

Am J Gastroenterol. 2005 Nov;100(11):2463-71.

PMID:
16279901
[PubMed - indexed for MEDLINE]
18.

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL.

Hepatology. 2001 Oct;34(4 Pt 1):785-91.

PMID:
11584376
[PubMed - indexed for MEDLINE]
19.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.

J Med Virol. 2007 Nov;79(11):1664-70.

PMID:
17854034
[PubMed - indexed for MEDLINE]
20.

A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.

Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD.

J Dig Dis. 2009 May;10(2):131-7. doi: 10.1111/j.1751-2980.2009.00375.x.

PMID:
19426396
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk